Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its ...

The Durham ID building in downtown Durham, NC holds the North Carolina office of Tune Therapeutics, a growing biotech startup moving into trials. Brian Gordon Launched from a Duke University lab ...

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced ... offices in Seattle and at the downtown Durham ID building. Series A and B are the two ...

(Tune Photos) Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.